EPC K1
Alternative Names: CHX 3107Latest Information Update: 29 Oct 2018
Price :
$50 *
At a glance
- Originator Senju Pharmaceutical
- Developer Senju Pharmaceutical; Toyama Chemical
- Class Antiulcers; Benzopyrans; Eye disorder therapies
- Mechanism of Action Immunosuppressants; Phospholipase A2 inhibitors; Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Allergic conjunctivitis; Cerebral infarction; Lung transplant rejection; Reperfusion injury; Stroke
Most Recent Events
- 05 Feb 2008 Discontinued - Phase-II for Cerebral infarction in Japan (unspecified route)
- 05 Feb 2008 Discontinued - Phase-II for Reperfusion injury in Japan (unspecified route)
- 05 Feb 2008 Discontinued - Phase-II for Reperfusion injury in USA (unspecified route)